Apoptotic effects of resveratrol, a grape polyphenol, onimatinib-sensitive and resistant K562 chronic myeloid leukemia cells

Anticancer Research

Volumn 32, Issue 7, 2012, Pages 2373-2678

  Can, Geylani ^a   Cakir, Zeynep ^a   Kartal, Melis ^a   Gunduz, Ufuk ^b   Baran, Yusuf ^a  

^a IZMIR INSTITUTE OF TECHNOLOGY   (Turkey)

^b MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Apoptosis; Chronic myeloid leukemia; Drug resistance; Imatinib resistance; K562 CML cells; Resveratrol

Indexed keywords

3 BIS[ 2 METHOXY 4 NITRO 5 SULFOPHENYL] 2H TETRAZOLIUM 5 CARBOXANILIDE INNER SALT; CASPASE 3; FLUORESCEIN ISOTHIOCYANATE; IMATINIB; LIPOCORTIN 5; MATRIX METALLOPROTEINASE; RESVERATROL; TETRAZOLE DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CASPASE 7; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; STILBENE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG SENSITIVITY; ENZYME ACTIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; LEUKEMIA CELL LINE; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FOLDING; CELL STRAIN K 562; DOSE RESPONSE; DRUG RESISTANCE; METABOLISM; PATHOLOGY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CASPASE 7; CELL GROWTH PROCESSES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MEMBRANE POTENTIAL, MITOCHONDRIAL; PIPERAZINES; PYRIMIDINES; STILBENES;

EID: 84865679765     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Koca E and Haznedaroglu IC: Imatinib mesylate and the management of chronic myeloid leukemia (CML). Turk J Hematol 22: 161-172, 2005.
2. Jagani Z, Singh A and Khosravi-Far R: FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis. Biochim Biophys Acta 1785: 63-84, 2008.
3. Frazer R, Irvine AE and McMullin MF: Chronic myeloid leukaemia in the 21st century. Ulster Med J 76: 8-17, 2007.
4. Maekawa T, Ashihara E and Kimura S: The BCR-ABL tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. Int J Clin Oncol 12: 327-340, 2007.
5. Mauro MJ: Defining and managing imatinib resistance. Hematology Am Soc Hematol Educ Program pp. 219-225, 2006.
6. Quintas-Cardama A, Kantarjian HM and Cortes JE: Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control 16: 122-131, 2009.
7. Baran Y, Salas A, Senkal CE, Gunduz U, Bielawski J, Obeid LM and Ogretmen B: Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J Biol Chem 282: 10922-10934, 2007.
8. Santos FP and Ravandi F: Advances in treatment of chronic myelogenous leukemia new treatment options with tyrosine kinase inhibitors. Leuk Lymphoma 2: 16-26, 2009.
9. Kundu JK and Surh YJ: Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett 269 : 243-261, 2008.
10. Ulrich S, Huwiler A, Loitsch S, Schmidt H and Stein JM: De novo ceramide biosynthesis is associated with resveratrol-induced inhibition of ornithine decarboxylase activity. Biochem Pharmacol 74 : 281-289, 2007.
11. Sahin F, Avci CB, Avcu F, Ural AU, Sarper M, Hisil Y, Omay SB and Saydam G: Red grape seed extract and its compound resveratrol exert cytotoxic effects on various human cancer lines. Turk J Hematol 24 : 102-109, 2007.
12. Gatz SA and Wiesmuller L: Take a break-resveratrol in action on DNA. Carcinogenesis 29 : 321-332, 2008.
13. Liao HF, Kuo CD, Yang YC, Lin CP, Tai HC, Chen YY and Chen YJ: Resveratrol enhances radiosensitivity of human non-small cell lung cancer NCI-H838 cells accompanied by inhibition of nuclear factor-kappa B activation. J Radiat Res (Tokyo) 46: 387-393, 2005.
14. Scarlatti F, Sala G, Ricci C, Maioli C, Milani F, Minella M, Botturi M and Ghidoni R: Resveratrol sensitization of DU145 prostate cancer cells to ionizing radiation is associated with ceramide increase. Cancer Lett 253 : 124-130, 2007.
15. Park JS, Kim KM, Kim MH, Chang HJ, Baek MK, Kim SM and Jung YD: Resveratrol inhibits tumor cell adhesion to endothelial cells by blocking ICAM-1 expression. Anticancer Res 29: 355-362, 2009.
16. Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U, Nair AS, Shishodia S and Aggarwal BB: Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 109 : 2293-2302, 2007.
17. Ekiz HA, Can G, Gunduz U and Baran Y: Nilotinib significantly induces apoptosis in imatinib-resistant K562 cells with wild-type BCR-ABL, as effectively as in parental sensitive counterparts. Hematology 15 : 33-38, 2010.
18. Cakir Z, Saydam G, Sahin F and Baran Y: The roles of bioactive sphingolipids in resveratrol-induced apoptosis in HL60: acute myeloid leukemia cells. J Cancer Res Clin Oncol 137: 279-286, 2011.
19. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA and Zigler AJ: Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96 : 925-932, 2000.
20. Sjoblom T, Shimizu A, O'Brien KP, Pietras K, Dal Cin P, Buchdunger E, Dumanski JP, Ostman A and Heldin CH: Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 61: 5778-5783, 2001.
21. Druker BJ and Lydon NB: Lessons learned from the development of an ABL tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105: 3-7, 2000.
22. Liegl-Atzwanger B, Fletcher JA and Fletcher CD: Gastrointestinal stromal tumors. Virchows Arch 456: 111-127, 2010.
23. Rosti G, Castagnetti F, Gugliotta G, Palandri F, Martinelli G and Baccarani M: Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'. Leuk Lymphoma 51: 583-591, 2010.
24. Gledhill JR, Montgomery MG, Leslie AG and Walker JE: Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols. Proc Natl Acad Sci USA 104: 13632-13637, 2007.
25. Le Corre L, Chalabi N, Delort L, Bignon YJ and Bernard-Gallon DJ: Resveratrol and breast cancer chemoprevention: molecular mechanisms. Mol Nutr Food Res 49: 462-471, 2005.
26. Aziz MH, Nihal M, Fu VX, Jarrard DF and Ahmad N: Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3'-kinase/AKT pathway and BCL-2 family proteins. Mol Cancer Ther 5: 1335-1341, 2006.
27. Kartal M, Saydam G, Sahin and Baran Y: Resveratrol triggers apoptosis by increasing intracellular concentrations of ceramides in chronic myeloid leukemia cells. Nutr Cancer 63(4): 637-644, 2011.
28. Ragione FD, Cucciolla V, Criniti V, Indaco S, Borriello A and Zappia V: p21 Cip1 gene expression is modulated by Egr1: a novel regulatory mechanism involved in the resveratrol antiproliferative effect. J Biol Chem 278: 23360-23368, 2003.
29. Ragione FD, Cucciolla V, Borriello A, Pietra VD, Racioppi L, Soldati G, Manna C, Galletti P and Zappia V: Resveratrol arrests the cell division cycle at S/G2 phase transition. Biochem Biophys Res Commun 250: 53-58, 1998.